Sanofi to Acquire Vicebio to Strengthen Respiratory Vaccines
Tuesday, July 22, 2025
Sanofi has announced an agreement to acquire Vicebio.
This acquisition will add an early-stage vaccine candidate targeting respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) to Sanofi’s portfolio, expanding its presence in respiratory vaccines.
The deal includes access to Vicebio’s ‘Molecular Clamp’ technology, which helps stabilise viral proteins in their natural form. This enables the immune system to better recognise and respond to viruses. The technology also supports the development of fully liquid combination vaccines, which can be stored at standard refrigeration temperatures (2–8°C). These vaccines do not require freezing or freeze-drying, simplifying storage and distribution. They can also be delivered in prefilled syringes, improving safety and ease of use across healthcare settings.
With this acquisition, Sanofi broadens its non-mRNA vaccine pipeline for RSV and adds potential coverage for hMPV. This complements the company’s existing work in flu and RSV prevention, offering more options for healthcare providers and patients.
Vicebio’s pipeline includes VXB-241, a bivalent vaccine candidate for RSV and hMPV currently in a Phase 1 exploratory trial in older adults, and VXB-251, a preclinical trivalent candidate targeting RSV, hMPV, and parainfluenza virus Type 3 (PIV3).
These three viruses are major contributors to lower respiratory tract infections, particularly in older adults. They often cause similar symptoms, such as cough and fever, and tend to circulate together, contributing to seasonal peaks in respiratory illnesses.
The acquisition reflects Sanofi’s continued focus on vaccine innovation and its aim to develop next-generation combination vaccines that offer broader protection with a single immunisation.
Source: sanofi.com
